Steigerwald Gordon & Koch Inc. Has $25.44 Million Position in Stryker Co. (NYSE:SYK)

Steigerwald Gordon & Koch Inc. decreased its holdings in Stryker Co. (NYSE:SYK) by 1.3% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 68,349 shares of the medical technology company’s stock after selling 933 shares during the quarter. Stryker accounts for about 2.8% of Steigerwald Gordon & Koch Inc.’s holdings, making the stock its 8th biggest holding. Steigerwald Gordon & Koch Inc.’s holdings in Stryker were worth $25,443,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of SYK. Norges Bank bought a new position in Stryker in the fourth quarter worth approximately $1,710,744,000. GAMMA Investing LLC raised its stake in Stryker by 43,226.8% in the first quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company’s stock worth $772,390,000 after buying an additional 2,070,133 shares in the last quarter. Raymond James Financial Inc. bought a new position in Stryker in the fourth quarter worth approximately $353,394,000. FMR LLC raised its stake in Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock worth $2,892,946,000 after buying an additional 727,850 shares in the last quarter. Finally, Proficio Capital Partners LLC raised its stake in Stryker by 52,520.8% in the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock worth $214,660,000 after buying an additional 595,061 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

NYSE SYK opened at $382.87 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock’s fifty day moving average price is $369.68 and its 200 day moving average price is $376.11. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a market cap of $146.14 billion, a price-to-earnings ratio of 49.34, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same period in the prior year, the company earned $2.50 earnings per share. The firm’s revenue was up 11.9% on a year-over-year basis. As a group, equities research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker’s payout ratio is 45.41%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now directly owns 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Truist Financial upped their price target on Stryker from $390.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, May 5th. Evercore ISI reduced their price target on Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Citigroup reaffirmed a “buy” rating and set a $455.00 price target (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.